Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC
6 July 2015 | By Victoria White
Results from a study on the efficacy of cetuximab plus FOLFOX chemo as second-line treatment for patients with mCRC were presented at the ESMO 2015 congress...